Clínic Barcelona

AEMPS authorizes Phase IIb clinical trial of HIPRA Covid-19 vaccine

The biotechnological pharmaceutical company HIPRA has received authorization from the Spanish Agencyfor Medicines and Health Products (AEMPS) to  start Phase IIb of the clinical trial of the HIPRA vaccine against Covid-19. 

Related contents
Keep reading about:

Related news